as per annexure enclosed
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty 100 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals Enterprise Limited reported strong FY2026 results with standalone revenue from operations growing 13.7% to Rs 93,262 million and consolidated revenue up 15.8% to Rs 252,285 million. Consolidated PAT surged 33% to Rs 20,027 million with EPS of Rs 135.04. The Board approved two major corporate actions: merger of wholly-owned subsidiary Apollo Hospitals North Limited into the company, and a transaction where Apollo Health and Lifestyle Limited divests stakes in Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India (Cloudnine) at an enterprise value of Rs 15,500 million. Dr. Prathap C Reddy was re-appointed as Executive Chairman for two years, and Ms. Rama Bijapurkar's appointment as Independent Director was renewed for five years. Auditors issued unmodified opinions on both standalone and consolidated financials.
Apollo Hospitals delivered robust 33% PAT growth on consolidated basis, signaling strong operational performance across healthcare services, retail health, and digital pharmacy segments. The strategic transactions and merger announcements indicate active portfolio restructuring. Shareholders can expect total dividend of Rs 20 per share for FY2026.